Cargando…
Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
SC9-2 is a recombinant Marek's disease virus (MDV) strain lacking the meq oncogene. Previous study demonstrated that SC9-2 virus provides good protection against challenge with a very virulent MDV rMd5, but it induces immunosuppressive effects in specific pathogen-free (SPF) chickens. In the pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587640/ https://www.ncbi.nlm.nih.gov/pubmed/32241474 http://dx.doi.org/10.1016/j.psj.2019.11.059 |
_version_ | 1783600216527601664 |
---|---|
author | Sun, Peng Cui, Ning Liu, Linqing Su, Shuai Cheng, Ziqiang Chen, Ruiai Li, Yanpeng Cui, Zhizhong |
author_facet | Sun, Peng Cui, Ning Liu, Linqing Su, Shuai Cheng, Ziqiang Chen, Ruiai Li, Yanpeng Cui, Zhizhong |
author_sort | Sun, Peng |
collection | PubMed |
description | SC9-2 is a recombinant Marek's disease virus (MDV) strain lacking the meq oncogene. Previous study demonstrated that SC9-2 virus provides good protection against challenge with a very virulent MDV rMd5, but it induces immunosuppressive effects in specific pathogen-free (SPF) chickens. In the present study, SC9-2 was serially passaged on chicken embryo fibroblast (CEF) cell cultures. The pathogenicity and immune efficacy of SC9-2/10(th) and SC9-2/40(th) against rMd5 were evaluated. Animal experimental results showed that SC9-2/10(th) and SC9-2/40(th) showed no lethality or tumorigenicity in SPF chickens. Body weight of chickens inoculated with SC9-2/40(th) were significantly higher than that of the chickens inoculated with SC9-2/10(th) but lower than that of the uninoculated controls. The severity of bursa and thymus atrophy (BTA) and spleen enlargement in SC9-2/40(th)-inoculated chickens were also weaker than the SC9-2/10(th)-inoculated ones but stronger than the uninoculated controls. Chickens inoculated with SC9-2/40(th) and SC9-2/10(th) showed similar antibody levels induced by H9N2 subtype avian influenza virus/Newcastle disease virus inactivated vaccines, both of which were lower than the uninoculated controls. Replication of SC9-2/40(th) was significantly lower than SC9-2/10(th) in feather follicle epithelium (FFE) of infected chickens. The immune protection index of SC9-2/40(th) was also lower than that of SC9-2/10(th), but the difference was not significantly, and both of which were significant higher than that of the commercial MDV vaccine CVI988/Rispens. The results of our studies demonstrated that SC9-2/40(th) showed weaker severity of BTA, spleen enlargement, and body weight loss and lower replication level in FFE than SC9-2/10(th) in SPF chickens. However, SC9-2/40(th) was able to confer better immune protection as compared with CVI988/Rispens vaccination in SPF chickens. In conclusion, serially attenuation of SC9-2 in CEFs reduced the lymphoid organ atrophy and replication in SPF chickens, and the immune protective efficacy of attenuated viruses was still superior than CVI988/Rispens. |
format | Online Article Text |
id | pubmed-7587640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75876402020-10-27 Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus Sun, Peng Cui, Ning Liu, Linqing Su, Shuai Cheng, Ziqiang Chen, Ruiai Li, Yanpeng Cui, Zhizhong Poult Sci Immunology, Health and Disease SC9-2 is a recombinant Marek's disease virus (MDV) strain lacking the meq oncogene. Previous study demonstrated that SC9-2 virus provides good protection against challenge with a very virulent MDV rMd5, but it induces immunosuppressive effects in specific pathogen-free (SPF) chickens. In the present study, SC9-2 was serially passaged on chicken embryo fibroblast (CEF) cell cultures. The pathogenicity and immune efficacy of SC9-2/10(th) and SC9-2/40(th) against rMd5 were evaluated. Animal experimental results showed that SC9-2/10(th) and SC9-2/40(th) showed no lethality or tumorigenicity in SPF chickens. Body weight of chickens inoculated with SC9-2/40(th) were significantly higher than that of the chickens inoculated with SC9-2/10(th) but lower than that of the uninoculated controls. The severity of bursa and thymus atrophy (BTA) and spleen enlargement in SC9-2/40(th)-inoculated chickens were also weaker than the SC9-2/10(th)-inoculated ones but stronger than the uninoculated controls. Chickens inoculated with SC9-2/40(th) and SC9-2/10(th) showed similar antibody levels induced by H9N2 subtype avian influenza virus/Newcastle disease virus inactivated vaccines, both of which were lower than the uninoculated controls. Replication of SC9-2/40(th) was significantly lower than SC9-2/10(th) in feather follicle epithelium (FFE) of infected chickens. The immune protection index of SC9-2/40(th) was also lower than that of SC9-2/10(th), but the difference was not significantly, and both of which were significant higher than that of the commercial MDV vaccine CVI988/Rispens. The results of our studies demonstrated that SC9-2/40(th) showed weaker severity of BTA, spleen enlargement, and body weight loss and lower replication level in FFE than SC9-2/10(th) in SPF chickens. However, SC9-2/40(th) was able to confer better immune protection as compared with CVI988/Rispens vaccination in SPF chickens. In conclusion, serially attenuation of SC9-2 in CEFs reduced the lymphoid organ atrophy and replication in SPF chickens, and the immune protective efficacy of attenuated viruses was still superior than CVI988/Rispens. Elsevier 2020-01-22 /pmc/articles/PMC7587640/ /pubmed/32241474 http://dx.doi.org/10.1016/j.psj.2019.11.059 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Immunology, Health and Disease Sun, Peng Cui, Ning Liu, Linqing Su, Shuai Cheng, Ziqiang Chen, Ruiai Li, Yanpeng Cui, Zhizhong Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus |
title | Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus |
title_full | Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus |
title_fullStr | Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus |
title_full_unstemmed | Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus |
title_short | Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus |
title_sort | attenuation of a recombinant marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against marek's disease virus |
topic | Immunology, Health and Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587640/ https://www.ncbi.nlm.nih.gov/pubmed/32241474 http://dx.doi.org/10.1016/j.psj.2019.11.059 |
work_keys_str_mv | AT sunpeng attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT cuining attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT liulinqing attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT sushuai attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT chengziqiang attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT chenruiai attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT liyanpeng attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus AT cuizhizhong attenuationofarecombinantmareksdiseaseviruslackingthemeqoncogeneandevaluationonitsimmuneefficacyagainstmareksdiseasevirus |